The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

The answer turned out to be a cutting-edge treatment that few Americans know about, according to Roswell Park Comprehensive ...

Crown BioScience experts explore organoid models and high-content imaging to evaluate T-cell-targeted therapies and ...

Dr. Laura Finn brings new treatment options to Louisiana using genetically altered cells to treat blood cancer patients. Here ...

Researchers have unlocked a powerful new way to fight solid tumors using smart immune cells that stay active longer and hit ...

Seniors with cancer respond just as well as younger patients to immune checkpoint inhibitors -- drugs that take the brakes ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a study by researchers from the Johns ...

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy.

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseasesHOUSTON, April 22, ...